Induction of the p21/CDK6 pathway and alteration of the immune microenvironment by the stem cell marker CBX3 in melanoma DOI Creative Commons

Wanxian Chen,

Linsa Zhou,

Jingjing Jiang

и другие.

Stem Cell Research & Therapy, Год журнала: 2025, Номер 16(1)

Опубликована: Фев. 11, 2025

As one of the stem cell markers, chromobox protein homolog 3 (CBX3) participates in multiple signaling pathways that affect progression various tumors. However, role CBX3 melanoma remains unclear, and mechanisms by which may regulate immunotherapy outcome remain largely unknown. We used Cancer Genome Atlas, Genotype-Tissue Expression portal, Gene Omnibus database to estimate expression its prognostic effect melanoma. The proliferation migration cells were examined using CCK8, cloning, wound healing, transwell assays. on tumorigenesis was assessed an vivo animal model. cycle flow cytometry, levels cycle-related genes proteins with altered analyzed qPCR western blotting. function immune microenvironment studied single-cell RNA sequencing public databases. found highly expressed poor prognosis. promoted vitro. Functional analysis revealed regulates cycle, as it accelerated G1 S transition, decreased p21 expression, increased CDK6 expression. Finally, immune-related assays showed is immunogenic can change conclude marker, activates p21/CDK6 pathway alters

Язык: Английский

Polyoxometalate Nanomaterials for Tumor Phototherapy DOI Open Access
Xue Li, Xiangwei Liu, Tao Ying

и другие.

ChemistrySelect, Год журнала: 2025, Номер 10(5)

Опубликована: Фев. 1, 2025

Abstract Polyoxometalates (POM) are a class of inorganic metal oxides with distinctive structural characteristics, compositional versatility, high catalytic efficacy, and convenient storage properties. In recent years, POM have shown considerable potential for mimicking enzyme activities. Besides their biological activities, been demonstrated to possess the ability sense diseases perform synergistic therapies based on redox near‐infrared absorption Similar metallic nanoparticles organic materials, these clusters also exhibit photothermal imaging therapeutic Based this, current review focuses exclusively application in therapy tumors. Furthermore, advantages issues associated POM‐based nanomaterials tumor discussed analyzed.

Язык: Английский

Процитировано

1
Chimeric Antigen Receptor Cells Solid Tumor Immunotherapy Assisted by Biomaterials Tools DOI
Yujun Song, Yifan Wang,

Jianping Man

и другие.

ACS Applied Materials & Interfaces, Год журнала: 2025, Номер unknown

Опубликована: Фев. 4, 2025

Chimeric antigen receptor (CAR) immune cell therapies have revolutionized oncology, particularly in hematological malignancies, yet their efficacy against solid tumors remains limited due to challenges such as dense stromal barriers and immunosuppressive microenvironments. With advancements nanobiotechnology, researchers developed various strategies methods enhance the CAR tumor treatment. In this Review, we first outline structure mechanism of CAR-T (T, T cell), CAR-NK (NK, natural killer), CAR-M (M, macrophage) deeply analyze potential these cells treatment they face. Next, explore how biomaterials can optimize treatments by improving microenvironment, controlling release, promoting infiltration, enhancing efficacy. Finally, summarize current solutions, emphasize effective combination therapy, look forward its future clinical application strategies. This Review provides important theoretical perspectives practical guidance for development more

Язык: Английский

Процитировано

1
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy DOI Creative Commons
Anna De Lucia, L. Mazzotti, Anna Gaimari

и другие.

Frontiers in Immunology, Год журнала: 2025, Номер 16

Опубликована: Фев. 10, 2025

Over the past decades, significant progress has been made in understanding of non-small cell lung cancer (NSCLC) biology and tumor progression mechanisms, resulting development novel strategies for early detection wide-ranging care approaches. Since their introduction, over 20 years ago, targeted therapies with tyrosine kinase inhibitors (TKIs) have revolutionized treatment landscape NSCLC. Nowadays, remain gold standard many patients, but still they suffer from adverse effects, including unexpected toxicity intrinsic acquired resistance mutations, which lead to relapse. The adoption immune checkpoint (ICIs) 2015, offered exceptional survival benefits patients without targetable alterations. Despite this notable progress, challenges remain, as not all respond favorably ICIs, therapy can develop time. A crucial factor influencing clinical response immunotherapy is microenvironment (TME). TME pivotal orchestrating interactions between neoplastic cells system, growth outcomes. In review, we discuss how intricate relationship success survey current state intervention, a focus on forthcoming promising chimeric antigen receptor (CAR) T sets major obstacles CAR-T therapies, creating conditions that suppress response, inducing exhaustion. To enhance efficacy, specific efforts associated NSCLC, should definitely TME-related immunosuppression escape by combining blockades.

Язык: Английский

Процитировано

1
A Spatially Distributed Microneedle System for Bioorthogonal T Cell‐Guided Cancer Therapy DOI Creative Commons

Lanya Li,

Fei Wang, Shushan Mo

и другие.

Advanced Science, Год журнала: 2025, Номер unknown

Опубликована: Фев. 8, 2025

Chimeric antigen receptor (CAR)-T cell therapy represents a promising strategy for cancer treatment. However, the diversity of solid tumor antigens and poor infiltration CAR-T cells significantly hinder efficacy therapies against tumors. Here, spatially distributed microneedle system (SDMNS) is developed that leverages bioorthogonal reactions to activate guide endogenous T tumors effective destruction. The SDMNS consists two dissolving microneedles, each loaded with complementary groups applied separately lymph nodes sites. One dibenzocyclooctyne (DBCO)-modified antibodies activates labels them in nodes. other microneedle, containing N-azidoacetylmannosamine-tetraacylated (Ac4ManNAz) glycometabolic labeling cells, chemotactic factor IP10, directly site. vivo studies demonstrate effectively directs migration activated into Through click reaction, DBCO-modified conjugate azide (N3)-modified eliciting robust antitumor immune responses durable memory. offers novel overcomes heterogeneity by facilitating directed cells.

Язык: Английский

Процитировано

1
Welche Immuntherapien sind heute schon Standard? Und mit welchen Nebenwirkungen muss man bei Immuntherapien rechnen? DOI

Zhala Gasimova,

Cyrus Khandanpour,

Kim Barbara Luley

и другие.

Zentralblatt für Chirurgie - Zeitschrift für Allgemeine Viszeral- Thorax- und Gefäßchirurgie, Год журнала: 2025, Номер 150(02), С. 170 - 174

Опубликована: Апрель 1, 2025

Zusammenfassung Im Vergleich zu früheren Behandlungsstandards (einschl. Chemotherapie, Strahlentherapie und Chirurgie) hat die Immuntherapie bedeutende Verbesserungen für Patienten in Bezug auf Überleben Lebensqualität gebracht. ist letztlich eine Art Sammelbegriff Vielzahl unterschiedlichster Therapeutika. Immuntherapeutische Ansätze haben sich fest als ein neuer Pfeiler der Krebsversorgung etabliert, von den neoadjuvanten adjuvanten Ansätzen bis hin zur metastatischen Phase bei diversen Entitäten. In diesem Review-Artikel heben wir hervor, welche Immuntherapien heutzutage onkologischen Versorgung Standard sind, mit einem starken Fokus Immuncheckpoint-Inhibitoren (ICIs), deren Einschränkungen sowie häufig auftretenden Nebenwirkungen.

Процитировано

1
Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy DOI Creative Commons
Maryam Sahlolbei, Amirhossein Ahmadieh-Yazdi,

Mohadeseh Rostamipoor

и другие.

IntechOpen eBooks, Год журнала: 2024, Номер unknown

Опубликована: Май 15, 2024

Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of cancer immunotherapy, offering targeted approach to combat various hematologic malignancies. In this treatment, patient’s genetically modified T cells are extracted and transformed produce chimeric receptors (CARs) that exclusive cells. These altered identify, attach to, destroy when they reinfused back into patient, customized course therapy. While CAR therapy’s clinical success has been most evident cases acute lymphoblastic leukemia certain types lymphomas, ongoing research aims extend its applicability solid tumors. Despite promise, challenges like cytokine release syndrome high cost treatment remain. Nonetheless, heralds new era potentially curative for patients with otherwise refractory diseases.

Язык: Английский

Процитировано

5
Ferroptosis as a new tool for tumor suppression through lipid peroxidation DOI Creative Commons
Xin Yang, Yanqing Liu, Zhe Wang

и другие.

Communications Biology, Год журнала: 2024, Номер 7(1)

Опубликована: Ноя. 9, 2024

As a newly defined type of programmed cell death, ferroptosis is considered potent weapon against tumors due to its distinct mechanism from other types death. Ferroptosis triggered by the uncontrolled accumulation hydroperoxyl polyunsaturated fatty acid-containing phospholipids, also called lipid peroxidation. The peroxidation, generated through enzymatic and non-enzymatic mechanisms, drives changes in morphology destruction membrane integrity. Here, we dissect mechanisms induced enzymatically or non-enzymatically, summarize major metabolism pathways modulating provide insights into relationship between tumor suppression. In this review, discuss recent advances microenvironments prospect potential therapeutic application.

Язык: Английский

Процитировано

5
Exercise-augmented THSD7B exhibited a positive prognostic implication and tumor-suppressed functionality in pan-cancer DOI Creative Commons
Zhiwen Luo, Jin-guo Zhu,

Zhengyuan Fang

и другие.

Frontiers in Immunology, Год журнала: 2024, Номер 15

Опубликована: Авг. 5, 2024

Breast cancer, one of the most prevalent malignancies among women worldwide, has rising incidence rates. Physical activity, particularly exercise, emerged as a significant modifier cancer prognosis, influencing both tumor biology and patient outcomes.

Язык: Английский

Процитировано

4
Transition Metal (Molybdenum)-Doped Drug-like Conformational Nanoarchitectonics with Altered Valence States (Mn2+/Mn4+ and Mo5+/Mo6+) for Augmented Cancer Theranostics DOI

Hong‐Ying Xia,

Ying Zhao,

Ruo-Yin Meng

и другие.

Molecular Pharmaceutics, Год журнала: 2024, Номер 21(11), С. 5864 - 5879

Опубликована: Окт. 8, 2024

Despite the advancements in cancer therapy, delivering active pharmaceutical ingredients (APIs) using nanoparticles remains challenging due to failed conveyance of required drug payload, poor targeting ability, and biodistribution, hampering their clinical translation. Recently, appropriate design materials with intrinsic therapeutic functionalities has garnered enormous interest development various intelligent nanoplatforms. In this study, we demonstrate fabrication transition metal (molybdenum, Mo)-doped manganese dioxide (MnO2) nanoarchitectures, exhibiting diagnostic (magnetic resonance imaging, MRI) (chemodynamic CDT) functionalities. The facile hydrothermal approach-assisted Mo-doped MnO2 flower-like nanostructures offered tailorable morphologies altered dimensions, precise effects, exceptional biocompatibility, biodegradability tumor microenvironment. resultant defects doped Mo species exhibited peroxidase oxidase activities, improving glutathione (GSH) oxidation. two sets variable valence ion pairs (Mn2+/Mn4+ Mo5+/Mo6+) interplay could substantially improve Fenton-like reaction generate toxic hydroxyl radicals (•OH), thus achieving CDT-assisted antitumor effects. As inherent T1-MRI agents, these displayed excellent MRI efficacy vitro. Together, believe that conformational nanoarchitectures states potentiate drugless therapy pharmaceutics.

Язык: Английский

Процитировано

4
Systemic lupus erythematosus: pathogenesis and targeted therapy DOI Creative Commons
Xu Su, Hui Yu,

Qingqiang Lei

и другие.

Molecular Biomedicine, Год журнала: 2024, Номер 5(1)

Опубликована: Окт. 30, 2024

Abstract Systemic lupus erythematosus (SLE) is a multifaceted autoimmune disorder characterized by dysregulated immune responses and autoantibody production, which affects multiple organs varies in clinical presentation disease severity. The development of SLE intricate, encompassing dysregulation within the system, collapse immunological tolerance, genetic susceptibilities to disease, variety environmental factors that can act as triggers. This review provides comprehensive discussion pathogenesis treatment strategies focuses on progress status traditional emerging for SLE. Traditional have mainly employed non-specific approaches, including cytotoxic immunosuppressive drugs, antimalarials, glucocorticoids, NSAIDs. These are effective mitigating effects but they not complete cure often accompanied adverse reactions. Emerging targeted therapeutic other hand, aim control treat targeting B T cells, inhibiting their activation function, well abnormal system. A deeper understanding exploration new essential advance this complex disease.

Язык: Английский

Процитировано

4